Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06059495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

Study acronym: DEWI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (14)v5
  2. Enrollment increased: 59 → 89 participantsv4 Show 6 more changesShow less
    • Start date: Dec 18, 2023 to Jan 22, 2024
    • Trial sites expanded: 2 → 18 locations
    • Eligibility criteria expanded, about 340 words
    • Secondary endpoints: 6 to 14
    • Study description expanded, about 37 words
    • Study title shortened, about 1 word
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Jan 15, 2024 to Dec 18, 2023
    v3
  4. Start date: Sep 20, 2023 to Jan 15, 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study aims to determine whether surgery can be safely avoided in patients achieving a complete response, defined by negative endoscopy and tumor-free biopsies after treatment.
Trial Details
NCT Number NCT06059495
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Adenocarcinoma - GEJ, Gastric Adenocarcinoma
Enrollment 89 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov